★
KNSA
Kiniksa Pharmaceuticals International PLC · Biotechnology
FCF$164mC
Rev+56.7%A
D/E0.02A
P/E56.1xD+
PEG0.99B+
80Score
$52.861Y Target$57.09Near-term target
5Y Target$70.74Compound horizon
10Y Target$90.29Long-dated conviction
FCF$164mTTM · 03/26C
FCF $164m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+56.7%TTM YoYA
Revenue +56.7% — hypergrowth, top decile · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.02totalA
D/E 0.02 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E56.1xD+
P/E 56.1 — expensive; prices in flawless execution
PEG0.99proxyB+
PEG 0.99 — near fair value, classic Lynch benchmark (1.0) · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $4.1b. 12% off the 52-week high of $59.87. Revenue growing +57% — in hypergrowth territory. PEG 0.99 — paying under fair value for the growth rate.
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 56.1x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $57.09 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $70.74 at ~6% CAGR — dividend + buyback compounding. 10 yr $90.29 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · KNSA
Shares to buy
37
Position size
$1,956
3.9% of portfolio
Stop price
$39.64
25% below $52.86
$ at risk
$500.00
1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.